TY - JOUR
T1 - Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS
AU - Koch-Henriksen, Nils Iørgen
AU - Thygesen, Lau Caspar
AU - Sørensen, Per Soelberg
AU - Magyari, Melinda
PY - 2024/1
Y1 - 2024/1
N2 - BACKGROUND: Estimating the effect of disease-modifying treatment of MS in observational studies is impaired by bias from unmeasured confounders, in particular indication bias.OBJECTIVE: To show how instrumental variables (IVs) reduce bias.METHODS: All patients with relapsing onset of MS 1996-2010, identified by the nationwide Danish Multiple Sclerosis Registry, were followed from onset. Exposure was treatment index throughout the first 12 years from onset, defined as a cumulative function of months without and with medium- or high-efficacy treatment, and outcomes were hazard ratios (HRs) per unit treatment index for sustained Expanded Disability Scale Score (EDSS) 4 and 6 adjusted for age at onset and sex, without and with an IV. We used the onset cohort (1996-2000; 2001-2005; 2006-2010) as an IV because treatment index increased across the cohorts.RESULTS: We included 6014 patients. With conventional Cox regression, HRs for EDSS 4 and 6 were 1.15 [95% CI: 1.13-1.18] and 1.17 [1.13-1.20] per unit treatment index. Only with IVs, we confirmed a beneficial effect of treatment with HRs of 0.86 [0.81-0.91] and 0.82 [0.74-0.90].CONCLUSION: The use of IVs eliminates indication bias and confirms that treatment is effective in delaying disability. IVs could, under some circumstances, be an alternative to marginal structural models.
AB - BACKGROUND: Estimating the effect of disease-modifying treatment of MS in observational studies is impaired by bias from unmeasured confounders, in particular indication bias.OBJECTIVE: To show how instrumental variables (IVs) reduce bias.METHODS: All patients with relapsing onset of MS 1996-2010, identified by the nationwide Danish Multiple Sclerosis Registry, were followed from onset. Exposure was treatment index throughout the first 12 years from onset, defined as a cumulative function of months without and with medium- or high-efficacy treatment, and outcomes were hazard ratios (HRs) per unit treatment index for sustained Expanded Disability Scale Score (EDSS) 4 and 6 adjusted for age at onset and sex, without and with an IV. We used the onset cohort (1996-2000; 2001-2005; 2006-2010) as an IV because treatment index increased across the cohorts.RESULTS: We included 6014 patients. With conventional Cox regression, HRs for EDSS 4 and 6 were 1.15 [95% CI: 1.13-1.18] and 1.17 [1.13-1.20] per unit treatment index. Only with IVs, we confirmed a beneficial effect of treatment with HRs of 0.86 [0.81-0.91] and 0.82 [0.74-0.90].CONCLUSION: The use of IVs eliminates indication bias and confirms that treatment is effective in delaying disability. IVs could, under some circumstances, be an alternative to marginal structural models.
KW - Cohort Studies
KW - Humans
KW - Multiple Sclerosis, Relapsing-Remitting/drug therapy
KW - Multiple Sclerosis/drug therapy
KW - Proportional Hazards Models
KW - Registries
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85173753990&partnerID=8YFLogxK
U2 - 10.1177/13524585231201423
DO - 10.1177/13524585231201423
M3 - Journal article
C2 - 37787012
SN - 1352-4585
VL - 30
SP - 113
EP - 120
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 1
ER -